Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

• Status: Recruiting
• Trial end date: 2023-01-15
• Target enrollment: 0
• Participant gender: All

Summary

This phase IV trial studies the side effects and how well perampanel works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy. Perampanel is a drug used to treat seizures. Giving perampanel together with other anti-seizure drugs may work better in reducing seizure frequency in patients with high-grade glioma and focal epilepsy compared to alternate anti-seizure drugs alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Anticonvulsants; Carbamazepine; Clobazam; Gabapentin; Lacosamide; Lamotrigine; Phenobarbital; Phenytoin; Pregabalin; Rufinamide; Topiramate; Valproic Acid; Zonisamide

Criteria

Inclusion Criteria:

• The subject, or the subject's legally acceptable representative is willing to participate in a clinical trial, provides written informed consent, and subject provides written assent, as required by the Mayo Clinic Institutional Review Board (IRB) policy involving human subjects. In the event of subject lacking the capacity or losing the ability to consent, consent will be deferred to subject's legally acceptable representative

• Subjects that satisfy one of the following diagnostic criteria:

• Patients with established clinical diagnoses of biopsy-proven high-grade glioma and epilepsy refractory to at least 1, drug with a seizure frequency of at least 1 seizure episode per month prior to baseline visit

• Subjects with body weight of >= 40 kg and =< 125 kg at screening

Exclusion Criteria:

• Subject has serious cardiac, respiratory, renal, gastrointestinal, hematologic or other medical condition as determined by the investigator to potentially interfere with the study

• Subjects with glioblastoma not following Stupp protocol for treatment of glioblastoma

• History of status epilepticus in the 6 months prior to screening or a history of seizure clusters progressing to status epilepticus

• Clinically significant suicide risk as determined by the clinician

• Positive test result for drugs of abuse at baseline without documented history of stable use for medical purposes or past medical history of drug and/or alcohol abuse

• Pregnant or breast-feeding

• Subjects treated with PER prior to baseline

• Prior felony conviction disclosed by the patient or previously stated in medical record

• History of violent behavior

• Clinically significant laboratory abnormality at screening or baseline visits, as determined by the investigators

• Use of an investigational drug or device within 20 days prior to treatment day 1

• Repeated radiation therapy for tumor regrowth

• Subjects that plan to undergo tumor resection on or after baseline visit

• Uncontrolled psychiatric disorder at baseline

• Subjects who report active suicidal attempts or suicidality including subjects with a history of suicide attempts or suicidality determined to be clinically significant by investigators at screening

• Patients with previous surgical history of tumor resection

• Previous surgical history of brain-tumor resection

• Biopsy proving the presence of a high-grade glioma dated to over 6 months before time of recruitment